Phase I study of SOF10 in patients with advanced solid tumors

Phase I study of SOF10 in combination with antineoplastic drugs in patients with advanced solid tumors

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031200407

Enrollment

Registered

2021-03-10

Start date

2021-05-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid Tumor

Interventions

SOF10: Specified dose, IV Atezolizumab: Specified dose, IV

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Aged >20 years at time of informed consent - Eastern Cooperative Oncology Group(ECOG) Performance Status (PS) of 0 or 1 - Life expectancy >12 weeks from date of enrollment - Histologically or cytologically documented solid tumor - Advanced or recurrent cancer for which standard therapy is ineffective or inappropriate, or for which no standard therapy exists

Exclusion criteria

Exclusion criteria: - Concurrent or prior autoimmune disease - Uncontrolled diabetes mellitus - Concurrent New York Heart Association (NYHA) Class >II congestive heart failure, myocardial infarction, arrhythmia, or unstable angina, or a history thereof within 6 months before enrollment - Concurrent symptomatic cerebrovascular disorder or a history thereof within 6 months before enrollment

Design outcomes

Primary

Measure	Time frame
Safety, Phamacokinetics NCI CTCAE	—

Secondary

Measure	Time frame
Efficacy RECIST	—

Contacts

Public ContactClinical trials information

Chugai Pharmaceutical Co., Ltd.

clinical-trials@chugai-pharm.co.jp+81-120-189-706

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026